|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Antoni S, Ferlay J, Soerjomataram I, Znaor
A, Jemal A and Bray F: Bladder cancer incidence and mortality: A
global overview and recent trends. Eur Urol. 71:96–108. 2017.
View Article : Google Scholar
|
|
3
|
Song BN, Kim SK, Mun JY, Choi YD, Leem SH
and Chu IS: Identification of an immunotherapy-responsive molecular
subtype of bladder cancer. EBioMedicine. 50:238–245. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chou R, Selph SS, Buckley DI, Gustafson
KS, Griffin JC, Grusing SE and Gore JL: Treatment of
muscle-invasive bladder cancer: A systematic review. Cancer.
122:842–851. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Levi F, La Vecchia C, Randimbison L and
Franceschi S: Incidence of infiltrating cancer following
superficial bladder carcinoma. Int J Cancer. 55:419–421. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Witjes JA, Compérat E, Cowan NC, De Santis
M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG and Sherif A;
European Association of Urology: EAU guidelines on muscle-invasive
and metastatic bladder cancer: Summary of the 2013 guidelines. Eur
Urol. 65:778–792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu G, Xu Y, Cen X, Nandakumar KS, Liu S
and Cheng K: Targeting pattern-recognition receptors to discover
new small molecule immune modulators. Eur J Med Chem. 144:82–92.
2018. View Article : Google Scholar
|
|
9
|
Herrero-Beaumont G, Pérez-Baos S,
Sánchez-Pernaute O, Roman-Blas JA, Lamuedra A and Largo R:
Targeting chronic innate inflammatory pathways, the main road to
prevention of osteoarthritis progression. Biochem Pharmacol.
165:24–32. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Napetschnig J and Wu H: Molecular basis of
NF-κB signaling. Annu Rev Biophys. 42:443–468. 2013. View Article : Google Scholar :
|
|
11
|
Baldwin AS Jr: The NF-kappa B and I kappa
B proteins: New discoveries and insights. Annu Rev Immunol.
14:649–683. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Willems M, Dubois N, Musumeci L, Bours V
and Robe PA: IκBζ: An emerging player in cancer. Oncotarget.
7:66310–66322. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Horber S, Hildebrand DG, Lieb WS,
Lorscheid S, Hailfinger S, Schulze-Osthoff K and Essmann F: The
Atypical Inhibitor of NF-κB, IκBζ, controls macrophage
interleukin-10 expression. J Biol Chem. 291:12851–12861. 2016.
View Article : Google Scholar
|
|
14
|
Wu Z, Zhang X, Yang J, Wu G, Zhang Y, Yuan
Y, Jin C, Chang Z, Wang J, Yang X and He F: Nuclear protein
IkappaB-zeta inhibits the activity of STAT3. Biochem Biophys Res
Commun. 387:348–352. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nogai H, Wenzel SS, Hailfinger S, Grau M,
Kaergel E, Seitz V, Wollert-Wulf B, Pfeifer M, Wolf A, Frick M, et
al: IκB-ζ controls the constitutive NF-κB target gene network and
survival of ABC DLBCL. Blood. 122:2242–2250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamamoto M, Yamazaki S, Uematsu S, Sato S,
Hemmi H, Hoshino K, Kaisho T, Kuwata H, Takeuchi O, Takeshige K, et
al: Regulation of Toll/IL-1-receptor-mediated gene expression by
the inducible nuclear protein IkappaBzeta. Nature. 430:218–222.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Krappmann D: Shaping oncogenic NF-κB
activity in the nucleus. Blood. 122:2146–2147. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Coto-Segura P, Gonzalez-Lara L, Batalla A,
Eiris N, Queiro R and Coto E: NFKBIZ and CW6 in adalimumab response
among psoriasis patients: Genetic association and alternative
transcript analysis. Mol Diagn Ther. 23:627–633. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim Y, Lee YS, Yang JY, Lee SH, Park YY
and Kweon MN: The resident pathobiont Staphylococcus xylosus in
Nfkbiz-deficient skin accelerates spontaneous skin inflammation.
Sci Rep. 7:63482017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sangil A, Arranz MJ, Guerri-Fernandez R,
Perez M, Monzon H, Payeras A, Andres M, Torviso J, Ibanez L, Garau
J and Calbo E: Genetic susceptibility to invasive pneumococcal
disease. Infect Genet Evol. 59:126–131. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kerami Z, Duijvis NW, Vogels EW, van
Dooren FH, Moerland PD and Te Velde AA: Effect of interleukin-17 on
gene expression profile of fibroblasts from Crohn's disease
patients. J Crohns Colitis. 8:1208–1216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brennenstuhl H, Armento A, Braczysnki AK,
Mittelbronn M and Naumann U: IκBζ, an atypical member of the
inhibitor of nuclear factor kappa B family, is induced by
Y-irradiation in glioma cells, regulating cytokine secretion and
associated with poor prognosis. Int J Oncol. 47:1971–1980. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
van Kester MS, Borg MK, Zoutman WH,
Out-Luiting JJ, Jansen PM, Dreef EJ, Vermeer MH, van Doorn R,
Willemze R and Tensen CP: A meta-analysis of gene expression data
identifies a molecular signature characteristic for tumor-stage
mycosis fungoides. J Invest Dermatol. 132:2050–2059. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kakiuchi N, Yoshida K, Uchino M, Kihara T,
Akaki K, Inoue Y, Kawada K, Nagayama S, Yokoyama A, Yamamoto S, et
al: Frequent mutations that converge on the NFKBIZ pathway in
ulcerative colitis. Nature. 577:260–265. 2020. View Article : Google Scholar
|
|
25
|
Jiang BH and Liu LZ: PI3K/PTEN signaling
in angiogenesis and tumorigenesis. Adv Cancer Res. 102:19–65. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang X, Huang H and Young KH: The PTEN
tumor suppressor gene and its role in lymphoma pathogenesis. Aging
(Albany NY). 7:1032–1049. 2015. View Article : Google Scholar
|
|
27
|
Carracedo A and Pandolfi PP: The PTEN-PI3K
pathway: Of feedbacks and cross-talks. Oncogene. 27:5527–5541.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang X, Cheng Y, Li P, Tao J, Deng X,
Zhang X, Gu M, Lu Q and Yin C: A lentiviral sponge for miRNA-21
diminishes aerobic glycolysis in bladder cancer T24 cells via the
PTEN/PI3K/AKT/mTOR axis. Tumour Biol. 36:383–391. 2015. View Article : Google Scholar
|
|
29
|
Zununi Vahed S, Barzegari A, Rahbar Saadat
Y, Goreyshi A and Omidi Y: Leuconostoc mesenteroides-derived
anticancer pharmaceuticals hinder inflammation and cell survival in
colon cancer cells by modulating NF-κB/AKT/PTEN/MAPK pathways.
Biomed Pharmacother. 94:1094–1100. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou W, Fu XQ, Zhang LL, Zhang J, Huang X,
Lu XH, Shen L, Liu BN, Liu J, Luo HS, et al: The
AKT1/NF-kappaB/Notch1/PTEN axis has an important role in
chemoresistance of gastric cancer cells. Cell Death Dis.
4:e8472013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang Z, Fang S, Di Y, Ying W, Tan Y and Gu
W: Modulation of NF-κB/miR-21/PTEN pathway sensitizes non-small
cell lung cancer to cisplatin. PLoS One. 10:e01215472015.
View Article : Google Scholar
|
|
32
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant tumors. 7th edition.
Wiley-Blackwell; pp. 262–265. 2009
|
|
33
|
Sauter G, Algaba F, Amin MB, Busch C,
Cheville J, Gasser T, Grignon D, Hofstaedter F, Lopez-Beltran A and
Epstein J: Tumours of the urinary system: Non-invasive urothelial
neoplasias. World Health Organization Classification of Tumours:
Pathology and Genetics of Tumours of the Urinary System and Male
Genital Organs. Eble JN, Sauter G, Epstein JI and Sesterhenn I:
IARC Press; Lyon: pp. 89–157. 2004
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
35
|
Yang K, Xiao Y, Xu T, Yu W, Ruan Y, Luo P
and Cheng F: Integrative analysis reveals CRHBP inhibits renal cell
carcinoma progression by regulating inflammation and apoptosis.
Cancer Gene Ther. 27:607–618. 2020. View Article : Google Scholar :
|
|
36
|
Ersahin T, Tuncbag N and Cetin-Atalay R:
The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. 11:1946–1954.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kluth LA, Black PC, Bochner BH, Catto J,
Lerner SP, Stenzl A, Sylvester R, Vickers AJ, Xylinas E and Shariat
SF: Prognostic and prediction tools in bladder cancer: A
comprehensive review of the literature. Eur Urol. 68:238–253. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ishiguro-Oonuma T, Ochiai K, Hashizume K
and Morimatsu M: The role of IFN-γ in regulating Nfkbiz expression
in epidermal keratinocytes. Biomed Res. 36:103–107. 2015.
View Article : Google Scholar
|
|
39
|
Muromoto R, Tawa K, Ohgakiuchi Y, Sato A,
Saino Y, Hirashima K, Minoguchi H, Kitai Y, Kashiwakura JI, Shimoda
K, et al: IκB-ζ expression requires both TYK2/STAT3 activity and
IL-17-regulated mRNA stabilization. Immunohorizons. 3:172–185.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Keniry M and Parsons R: The role of PTEN
signaling perturbations in cancer and in targeted therapy.
Oncogene. 27:5477–5485. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Puzio-Kuter AM, Castillo-Martin M, Kinkade
CW, Wang X, Shen TH, Matos T, Shen MM, Cordon-Cardo C and
Abate-Shen C: Inactivation of p53 and Pten promotes invasive
bladder cancer. Genes Dev. 23:675–680. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tamura M, Gu J, Tran H and Yamada KM: PTEN
gene and integrin signaling in cancer. J Natl Cancer Inst.
91:1820–1828. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Corti F, Nichetti F, Raimondi A, Niger M,
Prinzi N, Torchio M, Tamborini E, Perrone F, Pruneri G, Di
Bartolomeo M, et al: Targeting the PI3K/AKT/mTOR pathway in biliary
tract cancers: A review of current evidences and future
perspectives. Cancer Treat Rev. 72:45–55. 2019. View Article : Google Scholar
|
|
45
|
Ediriweera MK, Tennekoon KH and Samarakoon
SR: Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer:
Biological and therapeutic significance. Semin Cancer Biol.
59:147–160. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xing X, Zhang L, Wen X, Wang X, Cheng X,
Du H, Hu Y, Li L, Dong B, Li Z and Ji J: PP242 suppresses cell
proliferation, metastasis, and angiogenesis of gastric cancer
through inhibition of the PI3K/AKT/mTOR pathway. Anticancer Drugs.
25:1129–1140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sathe A and Nawroth R: Targeting the
PI3K/AKT/mTOR pathway in bladder cancer. Methods Mol Biol.
1655:335–350. 2018. View Article : Google Scholar
|
|
48
|
Hou T, Zhou L, Wang L, Kazobinka G, Zhang
X and Chen Z: CLCA4 inhibits bladder cancer cell proliferation,
migration, and invasion by suppressing the PI3K/AKT pathway.
Oncotarget. 8:93001–93013. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li Z, Hong S and Liu Z: lncRNA LINC00641
predicts prognosis and inhibits bladder cancer progression through
miR-197-3p/KLF10/PTEN/PI3K/AKT cascade. Biochem Biophys Res Commun.
503:1825–1829. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang XG, Zhang T, Li CY, Zhang MH and
Chen FM: CD164 promotes tumor progression and predicts the poor
prognosis of bladder cancer. Cancer Med. 7:3763–3772. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li JY, Huang WX, Zhou X, Chen J and Li Z:
Numb inhibits epithelial-mesenchymal transition via
RBP-Jκ-dependent Notch1/PTEN/FAK signaling pathway in tongue
cancer. BMC Cancer. 19:3912019. View Article : Google Scholar
|
|
52
|
Li X, Dai Y and Xu J: miR-21 promotes
pterygium cell proliferation through the PTEN/AKT pathway. Mol Vis.
24:485–494. 2018.
|
|
53
|
Qin J, Fu M, Wang J, Huang F, Liu H,
Huangfu M, Yu D, Liu H, Li X, Guan X and Chen X: PTEN/AKT/mTOR
signaling mediates anticancer effects of epigallocatechin-3-gallate
in ovarian cancer. Oncol Rep. 43:1885–1896. 2020.PubMed/NCBI
|
|
54
|
Augello G, Puleio R, Emma MR, Cusimano A,
Loria GR, McCubrey JA, Montalto G and Cervello M: A PTEN inhibitor
displays preclinical activity against hepatocarcinoma cells. Cell
Cycle. 15:573–583. 2016. View Article : Google Scholar : PubMed/NCBI
|
